242 related articles for article (PubMed ID: 35385748)
1. Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy.
Rajkumar S; Berry D; Heney KA; Strong C; Ramsay L; Lajoie M; Alkallas R; Nguyen TT; Thomson C; Ahanfeshar-Adams M; Dankner M; Petrella T; Rose AAN; Siegel PM; Watson IR
Cell Rep; 2022 Apr; 39(1):110634. PubMed ID: 35385748
[TBL] [Abstract][Full Text] [Related]
2. Targeted Therapy for Melanomas Without BRAF V600 Mutations.
Menzer C; Hassel JC
Curr Treat Options Oncol; 2022 Jun; 23(6):831-842. PubMed ID: 35380338
[TBL] [Abstract][Full Text] [Related]
3. Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition.
Shattuck-Brandt RL; Chen SC; Murray E; Johnson CA; Crandall H; O'Neal JF; Al-Rohil RN; Nebhan CA; Bharti V; Dahlman KB; Ayers GD; Yan C; Kelley MC; Kauffmann RM; Hooks M; Grau A; Johnson DB; Vilgelm AE; Richmond A
Clin Cancer Res; 2020 Jul; 26(14):3803-3818. PubMed ID: 32234759
[TBL] [Abstract][Full Text] [Related]
4. Melanoma with genetic alterations beyond the BRAFV600 mutation: management and new insights.
Awada G; Neyns B
Curr Opin Oncol; 2022 Mar; 34(2):115-122. PubMed ID: 35050937
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological features and clinical outcomes associated with TP53 and BRAF
Kim DW; Haydu LE; Joon AY; Bassett RL; Siroy AE; Tetzlaff MT; Routbort MJ; Amaria RN; Wargo JA; McQuade JL; Kemnade J; Hwu P; Woodman SE; Roszik J; Kim KB; Gershenwald JE; Lazar AJ; Davies MA
Cancer; 2017 Apr; 123(8):1372-1381. PubMed ID: 27911979
[TBL] [Abstract][Full Text] [Related]
6. Combined RAF and MEK Inhibition to Treat Activated Non-V600 BRAF-Altered Advanced Cancers.
Rustgi N; Maria A; Toumbacaris N; Zhao H; Kargus K; Bryant M; Waksmundzki A; Aricescu I; Lefkowitz RA; Li BT; Chou J; Capanu M; de Stanchina E; Misale S; Shia J; Yaeger R
Oncologist; 2024 Jan; 29(1):15-24. PubMed ID: 37616543
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapies for cutaneous melanoma.
Kee D; McArthur G
Hematol Oncol Clin North Am; 2014 Jun; 28(3):491-505. PubMed ID: 24880943
[TBL] [Abstract][Full Text] [Related]
8. [Response of BRAF(L597Q)-mutant melanoma to trametinib : Targeted melanoma therapy beyond BRAF(V600) mutations].
Haase O; Angün O; Grätz V; Lüttmann N; Neumann A; Zillikens D; Terheyden P
Hautarzt; 2016 Aug; 67(8):648-52. PubMed ID: 27146499
[TBL] [Abstract][Full Text] [Related]
9. BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.
Dahlman KB; Xia J; Hutchinson K; Ng C; Hucks D; Jia P; Atefi M; Su Z; Branch S; Lyle PL; Hicks DJ; Bozon V; Glaspy JA; Rosen N; Solit DB; Netterville JL; Vnencak-Jones CL; Sosman JA; Ribas A; Zhao Z; Pao W
Cancer Discov; 2012 Sep; 2(9):791-7. PubMed ID: 22798288
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II Study.
Nebhan CA; Johnson DB; Sullivan RJ; Amaria RN; Flaherty KT; Sosman JA; Davies MA
Oncologist; 2021 Sep; 26(9):731-e1498. PubMed ID: 33861486
[TBL] [Abstract][Full Text] [Related]
11. The role of BRAF V600 mutation in melanoma.
Ascierto PA; Kirkwood JM; Grob JJ; Simeone E; Grimaldi AM; Maio M; Palmieri G; Testori A; Marincola FM; Mozzillo N
J Transl Med; 2012 Jul; 10():85. PubMed ID: 22554099
[TBL] [Abstract][Full Text] [Related]
12. Clinical Development of BRAF plus MEK Inhibitor Combinations.
Subbiah V; Baik C; Kirkwood JM
Trends Cancer; 2020 Sep; 6(9):797-810. PubMed ID: 32540454
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Dabrafenib and Trametinib in a Patient with Squamous-Cell Carcinoma, with Mutation p.D594G in
Grenda A; Krawczyk P; Targowska-Duda KM; Kieszko R; Paśnik I; Milanowski J
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674722
[TBL] [Abstract][Full Text] [Related]
14. COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma.
van Akkooi AC; Hauschild A; Long GV; Mandala M; Kicinski M; Govaerts AS; Klauck I; Ouali M; Lorigan PC; Eggermont AM
Future Oncol; 2023 Sep; 19(30):2017-2027. PubMed ID: 37665297
[TBL] [Abstract][Full Text] [Related]
15. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
Dankner M; Rose AAN; Rajkumar S; Siegel PM; Watson IR
Oncogene; 2018 Jun; 37(24):3183-3199. PubMed ID: 29540830
[TBL] [Abstract][Full Text] [Related]
16. Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors.
Ming Z; Lim SY; Kefford RF; Rizos H
Pigment Cell Melanoma Res; 2020 Mar; 33(2):345-357. PubMed ID: 31518489
[TBL] [Abstract][Full Text] [Related]
17. Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells.
Molnár E; Rittler D; Baranyi M; Grusch M; Berger W; Döme B; Tóvári J; Aigner C; Tímár J; Garay T; Hegedűs B
BMC Cancer; 2018 May; 18(1):542. PubMed ID: 29739364
[TBL] [Abstract][Full Text] [Related]
18. Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors.
Adashek JJ; Menta AK; Reddy NK; Desai AP; Roszik J; Subbiah V
Mol Cancer Ther; 2022 Jun; 21(6):871-878. PubMed ID: 35413124
[TBL] [Abstract][Full Text] [Related]
19. Non-V600E/K BRAF Mutations in Metastatic Melanoma: Molecular Description, Frequency, and Effectiveness of Targeted Therapy in a Large National Cohort.
Girod M; Dalle S; Mortier L; Dalac S; Leccia MT; Dutriaux C; Montaudié H; de Quatrebarbes J; Lesimple T; Brunet-Possenti F; Saiag P; Maubec E; Legoupil D; Stoebner PE; Arnault JP; Lefevre W; Lebbe C; Dereure O
JCO Precis Oncol; 2022 Nov; 6():e2200075. PubMed ID: 36356284
[TBL] [Abstract][Full Text] [Related]
20. TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy.
Thielmann CM; Matull J; Zaremba A; Murali R; Chorti E; Lodde G; Jansen P; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Kretz J; Möller I; Sucker A; Paschen A; Livingstone E; Zimmer L; Hadaschik E; Ugurel S; Schadendorf D; Griewank KG
Eur J Cancer; 2022 Jan; 161():99-107. PubMed ID: 34936949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]